当期文章

多发性骨髓瘤线粒体功能障碍研究进展

傅敏^1,2, 王泽元^1,2, 向若虹^1,2, 徐浩^1,2, 刘静^1,2, 萧小鹃^1,2,*

¹中南大学生命科学学院，长沙 410013；²中南大学血液学基础与应用湖南省重点实验室，长沙 410013

摘要

多发性骨髓瘤是血液系统发病率第二高的恶性肿瘤，目前仍然无法治愈，容易出现耐药和复发。线粒体作为细胞能量代谢与稳态调控的关键枢纽，其功能异常在多种癌症中被发现。多发性骨髓瘤的发生、发展和耐药与线粒体功能障碍也密切相关。现有研究表明，多发性骨髓瘤细胞可通过增强氧化磷酸化、重编程糖酵解、维持氧化还原稳态、调控钙稳态、线粒体质量控制，以及抑制线粒体依赖性凋亡等方式获得生存优势而逃避治疗。针对上述过程的多种药物和联合治疗策略已在临床前研究中显示出潜力。本综述总结线粒体功能障碍在多发性骨髓瘤发展和耐药中的主要作用，以及相关靶向治疗的研究进展，为多发性骨髓瘤的靶向治疗提供新思路。

关键词： 多发性骨髓瘤; 线粒体功能障碍; 靶向治疗; 耐药

Research progress on mitochondrial dysfunction in multiple myeloma

FU Min^1,2, WANG Ze-Yuan^1,2, XIANG Ruo-Hong^1,2, XU Hao^1,2, LIU Jing^1,2, XIAO Xiao-Juan^1,2,*

¹School of Life Sciences, Central South University, Changsha 410013, China；²Key Laboratory of Basic and Applied Hematology in Hunan Province, Central South University, Changsha 410013, China

Abstract

Multiple myeloma ranks as the second most prevalent hematological malignancy. It remains incurable and is characterized by frequent drug resistance and disease relapse. Mitochondria, as a key hub for cellular energy metabolism and homeostasis regulation, have been found to have functional abnormalities in various cancers. The occurrence, progression and drug resistance of multiple myeloma are also closely linked to mitochondrial dysfunction. Existing research has shown that multiple myeloma cells acquire survival advantages and escape therapeutic elimination by enhancing oxidative phosphorylation, reprogramming glycolysis, maintaining redox homeostasis, regulating calcium homeostasis and mitochondrial quality control, as well as inhibiting mitochondria-dependent apoptosis. Multiple types of drugs and combination therapy strategies targeting the above processes have shown potential in preclinical studies. This review summarizes the main role of mitochondrial dysfunction in the development and drug resistance of multiple myeloma, as well as the research progress of targeted therapy, providing new ideas for targeted therapy of multiple myeloma.

Key words: multiple myeloma; mitochondrial dysfunction; targeted therapy; drug resistance

收稿日期：　　录用日期：

通讯作者：萧小鹃　　E-mail:

DOI: 10.13294/j.aps.2026.0081

引用本文：

傅敏, 王泽元, 向若虹, 徐浩, 刘静, 萧小鹃. 多发性骨髓瘤线粒体功能障碍研究进展[J]. 生理学报 2026; 78 (4): 851-866.

FU Min, WANG Ze-Yuan, XIANG Ruo-Hong, XU Hao, LIU Jing, XIAO Xiao-Juan. Research progress on mitochondrial dysfunction in multiple myeloma. Acta Physiol Sin 2026; 78 (4): 851-866 (in Chinese with English abstract).